New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

Equity Bottom-Up

<ul><li>Pacific Edge's (PEB) 1H24 result was modestly below expectations, driven by higher than expected costs.</li><li>While it has undertaken significant cost reductions to right size the business and manage cash flow this was not seen in its 1H24 result, with most changes occurring in 2Q24.</li><li>No additional details were given on the LCD coverage decision which is due by 26 July 2024. </li></ul>

Pacific Edge's (PEB) 1H24 result was modestly below expectations, driven by higher than expected costs.While it has undertaken significant cost reductions to right size the business and manage cash flow this was not seen in its 1H24 result, with most changes occurring in 2Q24.No additional details were given on the LCD coverage decision which is due by 26 July 2024. 

Pacific Edge - 1H24 Result — Kaiser Time

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>There were a lot of rebalance implementations in China on Friday, plus a few upcoming index changes that were announced during the week.</li>
<li>There are a lot of implementations this week, with <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200" target="_blank" data-smartkarma-citation="entities:26021:1" rel="noopener">KOSPI 200</a> and <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150</a> on Thursday and then others across a bunch of countries on Friday.</li>
<li>There were big inflows to <a href="https://www.smartkarma.com/entities/tracker-fund-of-hong-kong-ltd" target="_blank" data-smartkarma-citation="entities:29257:1" rel="noopener">Tracker Fund of Hong Kong (2800 HK)</a> during the week taking units outstanding to a new high. ETF inflows continue even as the market drops.</li>
</ul>


There were a lot of rebalance implementations in China on Friday, plus a few upcoming index changes that were announced during the week.
There are a lot of implementations this week, with KOSPI 200 and KOSDAQ 150 on Thursday and then others across a bunch of countries on Friday.
There were big inflows to Tracker Fund of Hong Kong (2800 HK) during the week taking units outstanding to a new high. ETF inflows continue even as the market drops.


Index Rebalance & ETF Flow Recap: NKY, TW Div+, ASX200, NZX50, Mom30, Top10EW, MVW, Rakuten Bank

<ul>
<li>
<a href="https://www.smartkarma.com/entities/gentrack-group-ltd" target="_blank" data-smartkarma-citation="entities:2752:1" rel="noopener">Gentrack (GTK NZ)</a> and <a href="https://www.smartkarma.com/entities/dorchester-pacific-ltd" target="_blank" data-smartkarma-citation="entities:1854:1" rel="noopener">Turners Automotive (TRA NZ)</a> will be added to the S&amp;P/NZX 50 Index while <a href="https://www.smartkarma.com/entities/synlait-milk-ltd" target="_blank" data-smartkarma-citation="entities:16298:1" rel="noopener">Synlait Milk (SML NZ)</a> and <a href="https://www.smartkarma.com/entities/pacific-edge-ltd" target="_blank" data-smartkarma-citation="entities:20261:1" rel="noopener">Pacific Edge (PEB NZ)</a> will be deleted.</li>
<li>There is a lot to trade on the stocks. The impact in terms of days of ADV appears high but historically there has been volume on implementation date.</li>
<li>The adds have jumped recently and there will be pre-positioning on the stocks. Not so much on the deletes.</li>
</ul>



Gentrack (GTK NZ) and Turners Automotive (TRA NZ) will be added to the S&amp;P/NZX 50 Index while Synlait Milk (SML NZ) and Pacific Edge (PEB NZ) will be deleted.
There is a lot to trade on the stocks. The impact in terms of days of ADV appears high but historically there has been volume on implementation date.
The adds have jumped recently and there will be pre-positioning on the stocks. Not so much on the deletes.


S&P/NZX 50 Index Rebalance: Two High Impact Changes Coming Up

<ul><li>The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayed</li><li>In the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption (where the future reimbursement path was highly uncertain and potentially multiple years away).</li><li>Future decision timeframes are unknown and this decision does not mean the finalised LCD will be discontinued.</li></ul>

The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17 July 2023 has been delayedIn the interim, PEB will continue to be reimbursed for its CMS tests (~77% of FY23 operating revenue) which is a clear near-term positive against prior expectations of a significant revenue reduction and business disruption (where the future reimbursement path was highly uncertain and potentially multiple years away).Future decision timeframes are unknown and this decision does not mean the finalised LCD will be discontinued.

Pacific Edge (PEB): LCD Update – Signs of Life

<ul><li>Pacific Edge's (PEB) CMS reimbursement will cease effective 17 July 2023. Materiality is very high — our prior base case assumed CMS would represent ~70% of group revenue in FY24, ~60% in FY25, and ~50% thereafter.</li><li>Upon further details from the company, how CMS coverage returns and the timing of it remains highly uncertain — our impression is it will be multiple years away (but we acknowledge there is a range of outcomes).</li><li>Our rating is now NEUTRAL having been UNDER REVIEW and we introduce a probability weighted valuation framework (based off three scenarios) with a target price of NZ$0.16.</li></ul>

Pacific Edge's (PEB) CMS reimbursement will cease effective 17 July 2023. Materiality is very high — our prior base case assumed CMS would represent ~70% of group revenue in FY24, ~60% in FY25, and ~50% thereafter.Upon further details from the company, how CMS coverage returns and the timing of it remains highly uncertain — our impression is it will be multiple years away (but we acknowledge there is a range of outcomes).Our rating is now NEUTRAL having been UNDER REVIEW and we introduce a probability weighted valuation framework (based off three scenarios) with a target price of NZ$0.16.

New Zealand

Pacific Edge Ltd is a biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. The Company has completed successful trials in bladder cancer detection and colorectal cancer prognosis.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pacific Edge (PEB NZ)

Pacific Edge - 1H24 Result — Kaiser Time

While it has undertaken significant cost reductions to right size the business and manage cash flow this was not seen in its 1H24 result, with most...

Forsyth Barr

Index Rebalance & ETF Flow Recap: NKY, TW Div+, ASX200, NZX50, Mom30, Top10EW, MVW, Rakuten Bank

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Brian Freitas

S&P/NZX 50 Index Rebalance: Two High Impact Changes Coming Up

As expected, Gentrack and Turners Auto will replace Synlait Milk and Pacific Edge in the NZX50 Index. The adds have jumped recently and there...

Brian Freitas

Pacific Edge (PEB): LCD Update – Signs of Life

The implementation of LCD, L35396 “Genetic Testing for Oncology” that would have resulted in Pacific Edge’s (PEB) CMS reimbursement ceasing on 17...

Forsyth Barr

Pacific Edge: CMiSery

Pacific Edge's (PEB) CMS reimbursement will cease effective 17 July 2023. Materiality is very high — our prior base case assumed CMS would...

Forsyth Barr

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)